Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs placebo with docetaxel + prednisone in metastatic androgen-independent prostate cancer
DRKS00003881Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Aflibercept arm with Placebo arm (2 arms). Started Apr 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on DRKS00003881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003881.